Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent β thalassaemia

British Journal of Haematology

Volumn 168, Issue 6, 2015, Pages 882-890

  Piga, Antonio ^a   Fracchia, Silvia ^a   Lai, Maria E ^b   Cappellini, Maria Domenica ^c   Hirschberg, Raimund ^d   Habr, Dany ^e   Wegener, Antje ^f   Bouillaud, Emmanuel ^e   Forni, Gian Luca ^g  

^a UNIVERSITY OF TURIN   (Italy)

^b Osp Regionale per le Microcitemie   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f NOVARTIS PHARMA K K   (Japan)

^g GALLIERA HOSPITAL   (Italy)

Author keywords

Deferasirox; Glomerular filtration rate; Iron chelation; Renal function; Thalassaemia

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; CREATININE; DEFERASIROX; FERRITIN; GLUTATHIONE TRANSFERASE P1; KIDNEY INJURY MOLECULE 1; MICROALBUMIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; UNCLASSIFIED DRUG; BENZOIC ACID DERIVATIVE; BIOLOGICAL MARKER; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CLINICAL ARTICLE; COUGHING; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DRUG EFFECT; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; FEVER; GLOMERULUS FILTRATION; HUMAN; IRON OVERLOAD; KIDNEY BLOOD FLOW; KIDNEY INJURY; KIDNEY PLASMA FLOW; LONG TERM CARE; MALE; MULTICENTER STUDY; OPEN STUDY; OROPHARYNX PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; RHINITIS; SHORT COURSE THERAPY; SIDE EFFECT; TREATMENT DURATION; UPPER ABDOMINAL PAIN; URINALYSIS; ADVERSE EFFECTS; BETA-THALASSEMIA; BLOOD; CHELATION THERAPY; CLINICAL TRIAL; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; KIDNEY CIRCULATION; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; URINE; YOUNG ADULT;

ADULT; BENZOATES; BETA-THALASSEMIA; BIOLOGICAL MARKERS; BLOOD TRANSFUSION; CHELATION THERAPY; CREATININE; FEMALE; FERRITINS; GLOMERULAR FILTRATION RATE; HEMODYNAMICS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MIDDLE AGED; RENAL CIRCULATION; TRIAZOLES; YOUNG ADULT;

EID: 84924082236     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13217     Document Type: Article

References (32)

1. Bhandari, S. & Galanello, R. (2012) Renal aspects of thalassaemia a changing paradigm. European Journal of Haematology, 89, 187-197.
2. Borgna-Pignatti, C., Rugolotto, S., De Stefano, P., Zhao, H., Cappellini, M.D., Del Vecchio, G.C., Romeo, M.A., Forni, G.L., Gamberini, M.R., Ghilardi, R., Piga, A. & Cnaan, A. (2004) Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica, 89, 1187-1193.
3. Cappellini, M.D., Cohen, A., Piga, A., Bejaoui, M., Perrotta, S., Agaoglu, L., Aydinok, Y., Kattamis, A., Kilinc, Y., Porter, J., Capra, M., Galanello, R., Fattoum, S., Drelichman, G., Magnano, C., Verissimo, M., Athanassiou-Metaxa, M., Giardina, B., Kourakli-Symeonidis, A., Janka-Schaub, G., Coates, T., Vermylen, C., Olivieri, N., Thuret, I., Opitz, H., Ressayre-Djaffer, C., Marks, P. & Alberti, D. (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood, 107, 3455-3462.
4. Cappellini, M.D., Porter, J.B., El-Beshlawy, A., Li, C.-K., Seymour, J.F., Elalfy, M., Gattermann, N., Giraudier, S., Lee, J.-W., Chan, L.L., Lin, K.-H., Rose, C., Taher, A., Thein, S.L., Viprakasit, V., Habr, D., Domokos, G., Roubert, B. & Kattamis, A. & on behalf of the EPIC study investigators (2010) Tailoring iron chelation by iron intake and serum ferritin trends: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias. Haematologica, 95, 557-566.
5. Cappellini, M.D., Bejaoui, M., Agaoglu, L., Canatan, D., Capra, M., Cohen, A., Drelichman, G., Economou, M., Fattoum, S., Kattamis, A., Kilinc, Y., Perrotta, S., Piga, A., Porter, J.B., Griffel, L., Dong, V., Clark, J. & Aydinok, Y. (2011) Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood, 118, 884-893.
6. Cockcroft, D.W. & Gault, M.H. (1976) Prediction of creatinine clearance from serum creatinine. Nephron, 16, 31-41.
7. Economou, M., Printza, N., Teli, A., Tzimouli, V., Tsatra, I., Papachristou, F. & Athanassiou-Metaxa, M. (2010) Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta Haematologica, 123, 148-152.
8. Fleming, J.S., Zivanovic, M.A., Blake, G.M., Burniston, M. & Cosgriff, P.S. (2004) Guidelines for the measurement of glomerular filtration rate using plasma sampling. Nuclear Medicine Communications, 25, 759-769.
9. Galanello, R., Piga, A., Forni, G.L., Bertrand, Y., Foschini, M.L., Bordone, E., Leoni, G., Lavagetto, A., Zappu, A., Longo, F., Maseruka, H., Hewson, N., Sechaud, R., Belleli, R. & Alberti, D. (2006) Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with β-thalassemia major. Haematologica, 91, 1343-1351.
10. Guo, X. & Nzerue, C. (2002) How to prevent, recognize, and treat drug-induced nephrotoxicity. Cleveland Clinic Journal of Medicine, 69, 289-312.
11. Hamed, E.A. & ElMelegy, N.T. (2010) Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study. Italian Journal of Pediatrics, 36, 39.
12. Jalali, A., Khalilian, H., Ahmadzadeh, A., Sarvestani, S., Rahim, F., Zandian, K. & Asar, S. (2011) Renal function in transfusion-dependent pediatric beta-thalassemia major patients. Hematology, 16, 249-254.
13. Koliakos, G., Papachristou, F., Koussi, A., Perifanis, V., Tsatra, I., Souliou, E. & Athanasiou, M. (2003) Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia. Clinical and Laboratory Haematology, 25, 105-109.
14. Koren, G., Kochavi-Atiya, Y., Bentur, Y. & Olivieri, N.F. (1991) The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. International Journal of Hematology, 54, 371-375.
15. Koyner, J.L., Vaidya, V.S., Bennett, M.R., Ma, Q., Worcester, E., Akhter, S.A., Raman, J., Jeevanandam, V., O'Connor, M.F., Devarajan, P., Bonventre, J.V. & Murray, P.T. (2010) Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clinical Journal of the American Society of Nephrology: CJASN, 5, 2154-2165.
16. Mohkam, M., Shamsian, B.S., Gharib, A., Nariman, S. & Arzanian, M.T. (2008) Early markers of renal dysfunction in patients with beta-thalassemia major. Pediatric Nephrology (Berlin, Germany), 23, 971-976.
17. Musallam, K.M. & Taher, A.T. (2012) Mechanisms of renal disease in beta-thalassemia. Journal of the American Society of Nephrology, 23, 1299.
18. Nakashima, R., Tomiguchi, S., Kojima, A., Takaki, Y., Tsuji, A. & Takahashi, M. (1996) Measurement of effective renal plasma flow (ERPF) with 123I-orthoiodohippurate (I-123-OIH). Radiation Medicine, 14, 147-150.
19. ® (deferasirox) US Prescribing Information. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/exjade.pdf.
20. Novartis Pharmaceuticals UK Ltd. (2014) Summary of Product Characteristics - EXJADE 125 mg, 250 mg, 500 mg dispersible tablets. Available at: http://www.medicines.org.uk/emc/medicine/18805/.
21. Pennell, D.J., Porter, J.B., Cappellini, M.D., El-Beshlawy, A., Chan, L.L., Aydinok, Y., Elalfy, M.S., Sutcharitchan, P., Li, C.K., Ibrahim, H., Viprakasit, V., Kattamis, A., Smith, G., Habr, D., Domokos, G., Roubert, B. & Taher, A. (2010) Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood, 115, 2364-2371.
22. Pennell, D., Porter, J.B., Cappellini, M.D., Chan, L.L., El-Beshlawy, A., Aydinok, Y., Ibrahim, H., Li, C.K., Viprakasit, V., Elalfy, M.S., Kattamis, A., Smith, G., Habr, D., Domokos, G., Roubert, B. & Taher, A. (2012) Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with beta-thalassemia major. Haematologica, 97, 842-848.
23. Ponticelli, C., Musallam, K.M., Cianciulli, P. & Cappellini, M.D. (2010) Renal complications in transfusion-dependent beta thalassaemia. Blood Reviews, 24, 239-244.
24. Porter, J., Galanello, R., Saglio, G., Neufeld, E.J., Vichinsky, E., Cappellini, M.D., Olivieri, N., Piga, A., Cunningham, M.J., Soulières, D., Gattermann, N., Tchernia, G., Maertens, J., Giardina, P., Kwiatkowski, J., Quarta, G., Jeng, M., Forni, G.L., Stadler, M., Cario, H., Debusscher, L., Della Porta, M., Cazzola, M., Greenberg, P., Alimena, G., Rabault, B., Gathmann, I., Ford, J.M., Alberti, D. & Rose, C. (2008) Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. European Journal of Haematology, 80, 168-176.
25. Porter, J.B., Elalfy, M.S., Taher, A.T., Aydinok, Y., Chan, L.L., Lee, S.H., Sutcharitchan, P., Habr, D., Martin, N. & El-Beshlawy, A. (2013) Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy. Annals of Hematology, 92, 211-219.
26. Sadeghi-Bojd, S., Hashemi, M. & Karimi, M. (2008) Renal tubular function in patients with beta-thalassaemia major in Zahedan, southeast Iran. Singapore Medical Journal, 49, 410-412.
27. Sánchez-González, P.D., López-Hernandez, F.J., Morales, A.I., Macías-Nuñez, J.F. & López-Novoa, J.M. (2011) Effects of deferasirox on renal function and renal epithelial cell death. Toxicology Letters, 203, 154-161.
28. Schetz, M., Dasta, J., Goldstein, S. & Golper, T. (2005) Drug-induced acute kidney injury. Current Opinion in Critical Care, 11, 555-565.
29. Vichinsky, E., Onyekwere, O., Porter, J., Swerdlow, P., Eckman, J., Lane, P., Files, B., Hassell, K., Kelly, P., Wilson, F., Bernaudin, F., Forni, G.L., Okpala, I., Ressayre-Djaffer, C., Alberti, D., Holland, J., Marks, P., Fung, E., Fischer, R., Mueller, B.U. & Coates, T. (2007) A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology, 136, 501-508.
30. ®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. British Journal of Haematology, 154, 387-397.
31. Vichinsky, E., Torres, M., Minniti, C.P., Barrette, S., Habr, D., Zhang, Y. & Files, B. (2013) Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology, 88, 1068-1073.
32. Voskaridou, E., Ladis, V., Kattamis, A., Hassapopoulou, E., Economou, M., Kourakli, A., Maragkos, K., Kontogianni, K., Lafioniatis, S., Vrettou, E., Koutsouka, F., Papadakis, A., Mihos, A., Eftihiadis, E., Farmaki, K., Papageorgiou, O., Tapaki, G., Maili, P., Theohari, M., Drosou, M., Kartasis, Z., Aggelaki, M., Basileiadi, A., Adamopoulos, I., Lafiatis, I., Galanopoulos, A., Xanthopoulidis, G., Dimitriadou, E., Mprimi, A., Stamatopoulou, M., Haile, E.D., Tsironi, M., Anastasiadis, A., Kalmanti, M., Papadopoulou, M., Panori, E., Dimoxenou, P., Tsirka, A., Georgakopoulos, D., Drandrakis, P., Dionisopoulou, D., Ntalamaga, A., Davros, I. & Karagiorga, M. (2012) A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births. Annals of Hematology, 91, 1451-1458.